Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 41 of 41 entries
Sorted by: Best Match Show Resources per page
Vincristine-induced cranial neuropathy.

Iranian journal of child neurology

Talebian A, Goudarzi RM, Mohammadzadeh M, Mirzadeh AS.
PMID: 24665331
Iran J Child Neurol. 2014;8(1):66-8.

Vincristine (VCR) is a vinca alkaloid that is used for treatment of many malignancies. The vinca alkaloids are neurotoxic, usually causing a peripheral neuropathy, but cranial neuropathies are rare as side effects. Described here is the case of a...

Cite
Talebian A, Goudarzi RM, Mohammadzadeh M, et al. Vincristine-induced cranial neuropathy. Iran J Child Neurol. 2014;8(1):66-8
Talebian, A., Goudarzi, R. M., Mohammadzadeh, M., & Mirzadeh, A. S. (2014). Vincristine-induced cranial neuropathy. Iranian journal of child neurology, 8(1), 66-8.
Talebian, Ahmad, et al. "Vincristine-induced cranial neuropathy." Iranian journal of child neurology vol. 8,1 (2014): 66-8.
Talebian A, Goudarzi RM, Mohammadzadeh M, Mirzadeh AS. Vincristine-induced cranial neuropathy. Iran J Child Neurol. 2014;8(1):66-8. PMID: 24665331; PMCID: PMC3943062.
Copy Download .nbib Format: NLM
Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda.

Journal of global oncology

Nzayisenga I, Segal R, Pritchett N, Xu MJ, Park PH, Mpanumusingo EV, Umuhizi DG, Goldstein DP, Berkowitz RS, Hategekimana V, Muhayimana C, Rubagumya F, Fadelu T, Tapela N, Mpunga T, Ghebre RG.
PMID: 28717722
J Glob Oncol. 2016 Apr 13;2(6):365-374. doi: 10.1200/JGO.2015.002568. eCollection 2016 Dec.

PURPOSE: Gestational trophoblastic neoplasia (GTN) is a highly treatable disease, most often affecting young women of childbearing age. This study reviewed patients managed for GTN at the Butaro Cancer Center of Excellence (BCCOE) in Rwanda to determine initial program...

Cite
Nzayisenga I, Segal R, Pritchett N, et al. Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol. 2016;2(6):365-374doi: 10.1200/JGO.2015.002568.
Nzayisenga, I., Segal, R., Pritchett, N., Xu, M. J., Park, P. H., Mpanumusingo, E. V., Umuhizi, D. G., Goldstein, D. P., Berkowitz, R. S., Hategekimana, V., Muhayimana, C., Rubagumya, F., Fadelu, T., Tapela, N., Mpunga, T., & Ghebre, R. G. (2016). Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda. Journal of global oncology, 2(6), 365-374. https://doi.org/10.1200/JGO.2015.002568
Nzayisenga, Ignace, et al. "Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda." Journal of global oncology vol. 2,6 (2016): 365-374. doi: https://doi.org/10.1200/JGO.2015.002568
Nzayisenga I, Segal R, Pritchett N, Xu MJ, Park PH, Mpanumusingo EV, Umuhizi DG, Goldstein DP, Berkowitz RS, Hategekimana V, Muhayimana C, Rubagumya F, Fadelu T, Tapela N, Mpunga T, Ghebre RG. Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol. 2016 Apr 13;2(6):365-374. doi: 10.1200/JGO.2015.002568. eCollection 2016 Dec. PMID: 28717722; PMCID: PMC5493245.
Copy Download .nbib Format: NLM
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

Cancer

Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS.
PMID: 34623638
Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 08.

BACKGROUND: The Children's Oncology Group clinical trial for intermediate risk rhabdomyosarcoma randomized participants to a combination of vincristine, dactinomycin, and cyclophosphamide (VAC) alone or VAC alternating with vincristine plus irinotecan (VAC/VI). Clinical outcomes were similar, but toxicity profiles differed....

Cite
Russell HV, Chi YY, Okcu MF, et al. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021;128(2):317-325doi: 10.1002/cncr.33917.
Russell, H. V., Chi, Y. Y., Okcu, M. F., Bernhardt, M. B., Rodriguez-Galindo, C., Gupta, A. A., & Hawkins, D. S. (2022). Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 128(2), 317-325. https://doi.org/10.1002/cncr.33917
Russell, Heidi V, et al. "Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group." Cancer vol. 128,2 (2022): 317-325. doi: https://doi.org/10.1002/cncr.33917
Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 08. PMID: 34623638; PMCID: PMC8738099.
Copy Download .nbib Format: NLM
Analysis of the interventions in antineoplastic therapy by a clinical pharmacy service at a tertiary hospital in Brazil.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

da Rocha C, Carlotto J, Zanis Neto J.
PMID: 34000918
J Oncol Pharm Pract. 2021 May 18;10781552211017650. doi: 10.1177/10781552211017650. Epub 2021 May 18.

BACKGROUND: Medication errors are avoidable occurrences that can assume clinically significant dimensions and impose relevant costs to the health system, especially in the context of antineoplastic therapy.OBJECTIVE: Assess the clinical significance and economic impacts of a clinical pharmaceutical service....

Cite
da Rocha C, Carlotto J, Zanis Neto J. Analysis of the interventions in antineoplastic therapy by a clinical pharmacy service at a tertiary hospital in Brazil. J Oncol Pharm Pract. 2021;10781552211017650doi: 10.1177/10781552211017650.
da Rocha, C., Carlotto, J., & Zanis Neto, J. (2021). Analysis of the interventions in antineoplastic therapy by a clinical pharmacy service at a tertiary hospital in Brazil. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552211017650. https://doi.org/10.1177/10781552211017650
da Rocha, Camile, et al. "Analysis of the interventions in antineoplastic therapy by a clinical pharmacy service at a tertiary hospital in Brazil." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. (2021): 10781552211017650. doi: https://doi.org/10.1177/10781552211017650
da Rocha C, Carlotto J, Zanis Neto J. Analysis of the interventions in antineoplastic therapy by a clinical pharmacy service at a tertiary hospital in Brazil. J Oncol Pharm Pract. 2021 May 18;10781552211017650. doi: 10.1177/10781552211017650. Epub 2021 May 18. PMID: 34000918.
Copy Download .nbib Format: NLM
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

Cancer

Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS.
PMID: 34623638
Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 08.

BACKGROUND: The Children's Oncology Group clinical trial for intermediate risk rhabdomyosarcoma randomized participants to a combination of vincristine, dactinomycin, and cyclophosphamide (VAC) alone or VAC alternating with vincristine plus irinotecan (VAC/VI). Clinical outcomes were similar, but toxicity profiles differed....

Cite
Russell HV, Chi YY, Okcu MF, et al. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021;128(2):317-325doi: 10.1002/cncr.33917.
Russell, H. V., Chi, Y. Y., Okcu, M. F., Bernhardt, M. B., Rodriguez-Galindo, C., Gupta, A. A., & Hawkins, D. S. (2022). Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 128(2), 317-325. https://doi.org/10.1002/cncr.33917
Russell, Heidi V, et al. "Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group." Cancer vol. 128,2 (2022): 317-325. doi: https://doi.org/10.1002/cncr.33917
Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 08. PMID: 34623638.
Copy Download .nbib Format: NLM
Showing 37 to 41 of 41 entries